| Autor: |
Tsvetkov IS; Research Institute of Human Morphology, Moscow, Russia. davedm66@gmail.com., Kosyreva AM; Research Institute of Human Morphology, Moscow, Russia., Mkhitarov VA; Research Institute of Human Morphology, Moscow, Russia., Postovalova EA; Research Institute of Human Morphology, Moscow, Russia., Khochanskiy DN; Research Institute of Human Morphology, Moscow, Russia., Makarova OV; Research Institute of Human Morphology, Moscow, Russia., Bredova OY; Research Institute of Human Morphology, Moscow, Russia., Ostrov VF; Research Institute of Human Morphology, Moscow, Russia. |
| Abstrakt: |
We studied morphological changes in the prostate ventral lobe, proliferative activity of the epithelium in prostate acini, and the levels of prolactin and prostate-specific antigen in the blood serum of Sprague-Dawley rats after repeated injections of sulpiride in a dose of 40 mg/ kg over 30 and 60 days and in 10 and 30 days after withdrawal. Morphological and morphometrical analysis of hyperplastic changes in the prostate ventral lobe was performed. Ki-67 + proliferating epithelial cells in the acini were counted. The dynamics of serum concentrations of prolactin and prostate-specific antigen was evaluated by ELISA. Morphological and morphometrical analysis and evaluation of the content of Ki-67 + cells demonstrated epithelium hyperplasia in the prostate ventral lobe after sulpiride treatment for 30 or 60 days and in 10 days after withdrawal, but serum level of prostate-specific antigen did not differ from the control. After 60-day sulpiride treatment and in 30 days after withdrawal, pronounced hyperplastic changes of prostate and elevated concentrations of prostate-specific antigen (but not prolactin) were observed. Thus, administration of sulpiride (40 mg/kg) to Sprague-Dawley rats for 60 days allows, by morphological criteria and serum level of prostate-specific antigen, to model stable hyperplastic changes in the prostate corresponding to benign prostatic hyperplasia in humans. |
Full text from SpringerLink